WST West Pharmaceutical Services Inc

  1. Stocks
  2. Healthcare
  3. NYSE: WST

Price (delayed)

$322.30

Market cap

$23.88B

P/E Ratio

68.87

Dividend/share

$0.51

EPS

$4.68

Enterprise value

$23.59B

Sector: Healthcare
Industry: Medical Instruments & Supplies
Website: https://www.westpharma.com/

Highlights

The net income has grown by 43% YoY and by 11% from the previous quarter
WST's EPS is up by 43% year-on-year and by 11% since the previous quarter
The stock's price to earnings (P/E) is 48% more than its 5-year quarterly average of 46.4 and 21% more than its last 4 quarters average of 56.8
West Pharmaceutical Services's quick ratio has decreased by 10% YoY

Key stats

What are the main financial stats of WST
Market
Shares outstanding
74.1M
Market cap
$23.88B
Enterprise value
$23.59B
Valuations
Price to earnings (P/E)
68.87
Price to book (P/B)
12.85
Price to sales (P/S)
11.09
EV/EBIT
55.27
EV/EBITDA
44.02
EV/Sales
10.99
Earnings
Revenue
$2.15B
EBIT
$426.9M
EBITDA
$536M
Free cash flow
$298.1M
Per share
EPS
$4.68
Free cash flow per share
$4.03
Book value per share
$25.09
Revenue per share
$29.05
TBVPS
$35.89
Balance sheet
Total assets
$2.79B
Total liabilities
$939.3M
Debt
$325.7M
Equity
$1.85B
Working capital
$870.3M
Liquidity
Debt to equity
0.18
Current ratio
2.73
Quick ratio
1.99
Net debt/EBITDA
-0.54
Margins
EBITDA margin
25%
Gross margin
35.8%
Net margin
16.1%
Operating margin
19%
Efficiency
Return on assets
13.8%
Return on equity
20.8%
Return on invested capital
23.8%
Return on capital employed
18.6%
Return on sales
19.9%
Dividend
Dividend yield
0.16%
DPS
$0.51
Payout ratio
10.9%

WST stock price

How has the West Pharmaceutical Services stock price performed over time
Intraday
0.14%
1 week
2.7%
1 month
13.79%
1 year
71.97%
YTD
13.76%
QTD
14.38%

Financial performance

How have West Pharmaceutical Services's revenue and profit performed over time
Revenue
$2.15B
Gross profit
$767.8M
Operating income
$406.9M
Net income
$346.2M
Gross margin
35.8%
Net margin
16.1%
The net income has grown by 43% YoY and by 11% from the previous quarter
WST's operating income is up by 37% YoY and by 11% from the previous quarter
The gross profit has grown by 27% YoY and by 8% from the previous quarter
WST's net margin is up by 23% year-on-year and by 5% since the previous quarter

Growth

What is West Pharmaceutical Services's growth rate over time

Valuation

What is West Pharmaceutical Services stock price valuation
P/E
68.87
P/B
12.85
P/S
11.09
EV/EBIT
55.27
EV/EBITDA
44.02
EV/Sales
10.99
The stock's price to earnings (P/E) is 48% more than its 5-year quarterly average of 46.4 and 21% more than its last 4 quarters average of 56.8
WST's EPS is up by 43% year-on-year and by 11% since the previous quarter
The price to book (P/B) is 91% higher than the 5-year quarterly average of 6.7 and 25% higher than the last 4 quarters average of 10.3
WST's equity is up by 18% year-on-year and by 8% since the previous quarter
The P/S is 105% above the 5-year quarterly average of 5.4 and 29% above the last 4 quarters average of 8.6
West Pharmaceutical Services's revenue has increased by 17% YoY and by 5% from the previous quarter

Efficiency

How efficient is West Pharmaceutical Services business performance
WST's return on invested capital is up by 27% year-on-year and by 8% since the previous quarter
West Pharmaceutical Services's ROE has increased by 26% YoY and by 7% from the previous quarter
The company's return on assets rose by 24% YoY and by 6% QoQ
WST's return on sales is up by 18% year-on-year and by 4.2% since the previous quarter

Dividends

What is WST's dividend history
DPS
$0.51
Dividend yield
0.16%
Payout ratio
10.9%
Recent dividends

Financial health

How did West Pharmaceutical Services financials performed over time
WST's total assets is 197% greater than its total liabilities
The total liabilities has increased by 22% year-on-year and by 9% since the previous quarter
WST's total assets is up by 19% year-on-year and by 8% since the previous quarter
WST's debt is 82% smaller than its equity
WST's equity is up by 18% year-on-year and by 8% since the previous quarter
The debt to equity has contracted by 14% YoY and by 5% from the previous quarter

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.